Evaluating the Cost-Effectiveness of Integrated Smoking Cessation within Lung Cancer Screening, using a Health Economic Model

You may also be interested in

Peer-reviewed publication

A Disease Progression Model Comparing the Long-Term Mobility and Respiratory Outcomes of Adults with Late-Onset Pompe Disease Receiving Cipaglucosidase Alfa Plus Miglustat versus Alglucosidase Alfa

YHEC authors: Amy Dymond, Will Green

Publication date: July 2026

Journal: Journal of Comparative Effectiveness Research

Abstract

AIM: Late-onset Pompe disease (LOPD) is a rare lysosomal disease primarily impacting muscle strength andrespiratory function. LOPD has a substantial burden despite the availability of alglucosidase alfa (alg). Patients often...

Peer-reviewed publication

Addressing Real-World Data Gaps: Estimating the UK Population Cost of Crohn’s Disease and Ulcerative Colitis Using A Flexible Cost-of-Illness Model Informed by the Optimal Patient Journey and IBDUK Patient Survey 2023

YHEC authors: Rachael MacDonald, Nick Hex, Barbara Uzdzinska, Jessica Pocock

Publication date: July 2026

Journal: BMC Health Services Research

Abstract

BACKGROUND: Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), are chronic conditions affecting around 500,000 people in the UK and carries rising prevalence and substantial economic...

Peer-reviewed publication

Next Generation Methods in Health Technology Assessment (HTA): Need, Rigor, and Implementability

YHEC authors: Melissa Pegg

Publication date: July 2026

Journal: International Journal of Technology Assessment in Healthcare

Abstract

The Health Technology Assessment International (HTAi) 2025 annual meeting featured three main plenaries to explore next generation (NextGen) evidence in health technology assessment (HTA). In this commentary we capture the...